CategoryAI
Variational AI
Headquarters: British Columbia
Summary
Partnership with Korean biotechs developing innovative small molecule (ADC payloads, TPD's, PROTACS, etc.) therapeutics using our Enki generative AI platform for drug discovery to create novel medicines across disease areas.
About
Variational AI has developed the Enki generative AI platform for small molecule drug discovery. Variational AI partners with leading biotechs and pharmas to rapidly generate novel and selective leads ready to go into lead optimization. Enki has pre-trained Enki on 873 targets for rapid lead generation. Enki also generates novel payloads for ADCs as well as degraders.